Dishman Carbogen Amcis Ltd
BSE:540701
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Dishman Carbogen Amcis Ltd
BSE:540701
|
IN |
|
Tenax Therapeutics Inc
NASDAQ:TENX
|
US |
|
SK Innovation Co Ltd
KRX:096775
|
KR |
|
G
|
GeneralFinance SpA
F:VG30
|
IT |
|
MainStreet Bancshares Inc
NASDAQ:MNSB
|
US |
|
KDDI Corp
TSE:9433
|
JP |
|
DNB Bank ASA
OSE:DNB
|
NO |
|
K
|
KDDI Corp
SWB:DIP
|
JP |
|
Z
|
Zinc Media Group PLC
LSE:ZIN
|
UK |
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is DCAL's stock price target?
Not Available
DCAL does not have any price targets made by Wall Street professionals.
What is the Revenue forecast for Dishman Carbogen Amcis Ltd?
Projected CAGR
4%
Over the last 8 years, the compound annual growth rate for Revenue has been 7%. The projected CAGR for the next 1 year is 4%.
What is the Gross Profit forecast for Dishman Carbogen Amcis Ltd?
Projected CAGR
-10%
Over the last 8 years, the compound annual growth rate for Gross Profit has been 9%. The projected CAGR for the next 5 years is -10%.
What is the Operating Income forecast for Dishman Carbogen Amcis Ltd?
Projected CAGR
34%
Over the last 8 years, the compound annual growth rate for Operating Income has been -1%. The projected CAGR for the next 1 year is 34%.
What is the Pre-Tax Income forecast for Dishman Carbogen Amcis Ltd?
Projected CAGR
-13%
Over the last 8 years, the compound annual growth rate for Pre-Tax Income has been -9%. The projected CAGR for the next 3 years is -13%.
What is the Net Income forecast for Dishman Carbogen Amcis Ltd?
Projected CAGR
-11%
Over the last 8 years, the compound annual growth rate for Net Income has been -6%. The projected CAGR for the next 3 years is -11%.
